TY - JOUR
T1 - Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy) methyl-2-nitroimidazole, a new18F-labeled 2-nitroimidazole analog
T2 - Clinical article
AU - Shibahara, Ichiyo
AU - Kumabe, Toshihiro
AU - Kanamori, Masayuki
AU - Saito, Ryuta
AU - Sonoda, Yukihiko
AU - Watanabe, Mika
AU - Iwata, Ren
AU - Higano, Shuichi
AU - Takanami, Kentaro
AU - Takai, Yoshihiro
AU - Tominaga, Teiji
PY - 2010/8
Y1 - 2010/8
N2 - Object. Assessment of hypoxic conditions in brain tumors is important for predicting tumor aggressiveness and treatment response. A new hypoxia imaging agent, 1-(2-[18F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2- nitroimidazole (FRP-170), with higher image contrast and faster clearance than preexisting hypoxia tracers for PET, was used to visualize hypoxic tissues in 8 patients with glioma. Methods. The FRP-170 was injected and PET imaging was performed 2 hours later in 8 patients, including 3 with glioblastoma multiforme, 2 with oligodendroglioma, and 1 each with diffuse astrocytoma, anaplastic ganglioglioma, and recurrent anaplastic astrocytoma. All 8 patients also underwent MR imaging, and some patients underwent [11C]methionine or [ 18F]fluorodeoxyglucose PET, and proton MR spectroscopy for comparison. Tissues obtained at biopsy or radical resection were immunostained with hypoxia-inducible factor-1α (HIF-1α) antibody for the confirmation of hypoxia, except in the patient with recurrent anaplastic astrocytoma who was treated using Gamma Knife surgery. Results. The FRP-170 PET images showed marked uptake with upregulation of HIF-1α in the 3 glioblastomas multiforme, and moderate uptake in the recurrent anaplastic astrocytoma and one oligodendroglioma, but no uptake in the other tumors. The FRP-170 PET images showed positive correlation with HIF-1α immunoreactivity and some correlation with FDG PET and MR imaging enhancement, but no correlation with [11C]methionine PET. Imaging with FRP-170 PET seemed to be more sensitive for detecting hypoxia than identifying the lactate peak on proton MR spectroscopy. Conclusions. Imaging with FRP-170 PET can visualize hypoxic lesions in patients with glioma, as confirmed by histological examination. This new method can assess tumor hypoxia preoperatively and noninvasively.
AB - Object. Assessment of hypoxic conditions in brain tumors is important for predicting tumor aggressiveness and treatment response. A new hypoxia imaging agent, 1-(2-[18F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2- nitroimidazole (FRP-170), with higher image contrast and faster clearance than preexisting hypoxia tracers for PET, was used to visualize hypoxic tissues in 8 patients with glioma. Methods. The FRP-170 was injected and PET imaging was performed 2 hours later in 8 patients, including 3 with glioblastoma multiforme, 2 with oligodendroglioma, and 1 each with diffuse astrocytoma, anaplastic ganglioglioma, and recurrent anaplastic astrocytoma. All 8 patients also underwent MR imaging, and some patients underwent [11C]methionine or [ 18F]fluorodeoxyglucose PET, and proton MR spectroscopy for comparison. Tissues obtained at biopsy or radical resection were immunostained with hypoxia-inducible factor-1α (HIF-1α) antibody for the confirmation of hypoxia, except in the patient with recurrent anaplastic astrocytoma who was treated using Gamma Knife surgery. Results. The FRP-170 PET images showed marked uptake with upregulation of HIF-1α in the 3 glioblastomas multiforme, and moderate uptake in the recurrent anaplastic astrocytoma and one oligodendroglioma, but no uptake in the other tumors. The FRP-170 PET images showed positive correlation with HIF-1α immunoreactivity and some correlation with FDG PET and MR imaging enhancement, but no correlation with [11C]methionine PET. Imaging with FRP-170 PET seemed to be more sensitive for detecting hypoxia than identifying the lactate peak on proton MR spectroscopy. Conclusions. Imaging with FRP-170 PET can visualize hypoxic lesions in patients with glioma, as confirmed by histological examination. This new method can assess tumor hypoxia preoperatively and noninvasively.
KW - FRP-170
KW - Glioma
KW - Hypoxia
KW - Hypoxia-inducible factor-1α
KW - Positron emission tomography
KW - Radioresistance
UR - http://www.scopus.com/inward/record.url?scp=77955596323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955596323&partnerID=8YFLogxK
U2 - 10.3171/2009.10.JNS09510
DO - 10.3171/2009.10.JNS09510
M3 - Article
C2 - 19895196
AN - SCOPUS:77955596323
SN - 0022-3085
VL - 113
SP - 358
EP - 368
JO - Journal of Neurosurgery
JF - Journal of Neurosurgery
IS - 2
ER -